NASDAQ:BOLT Bolt Biotherapeutics (BOLT) Stock Price, News & Analysis $4.95 +0.12 (+2.48%) As of 04:00 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Bolt Biotherapeutics Stock (NASDAQ:BOLT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Bolt Biotherapeutics alerts:Sign Up Key Stats Today's Range$4.58▼$5.0050-Day Range$3.91▼$5.3952-Week Range$3.91▼$9.25Volume25,684 shsAverage Volume25,504 shsMarket Capitalization$9.61 millionP/E RatioN/ADividend YieldN/APrice Target$41.00Consensus RatingHold Company Overview Bolt Biotherapeutics is a clinical-stage immuno-oncology company focused on developing novel targeted therapies that engage both innate and adaptive immune responses against cancer. The company’s proprietary Biologics-Driven Checkpoint (BDC) platform combines tumor-targeting antibodies with innate immune agonists to activate antigen-presenting cells within the tumor microenvironment, thereby promoting robust T-cell mediated tumor cell killing. Its lead candidate, BDC-1001, couples a HER2-directed monoclonal antibody with a Toll-like receptor 7/8 agonist and is currently in Phase I clinical trials for HER2-positive solid tumors. Additional preclinical programs under the BDC umbrella target other tumor antigens and immune checkpoints, aiming to broaden Bolt’s pipeline across multiple cancer types. Founded in 2015 and headquartered in Cambridge, Massachusetts, Bolt Biotherapeutics completed its initial public offering in August 2019 and trades on the Nasdaq under the symbol BOLT. The company has established research collaborations and material-transfer agreements with academic institutions and industry partners to support the advancement of its BDC candidates. By delivering innate immune stimulators directly to the tumor site, Bolt seeks to enhance antitumor efficacy while minimizing systemic toxicity commonly associated with broader immune-activating agents. While Bolt’s operations are based in the United States, the company maintains a global outlook through its international clinical trial network and potential strategic partnerships for development and commercialization. The management team is led by President and Chief Executive Officer Anna Protopapas, Ph.D., who brings over two decades of experience in oncology drug development. Supporting her are executives with deep expertise in clinical operations, regulatory affairs and business development, all aligned to advance Bolt’s immuno-oncology pipeline from early-stage studies toward later-phase trials. With its differentiated BDC approach, Bolt Biotherapeutics aims to generate proof-of-concept data that could support combination strategies with existing checkpoint inhibitors or other targeted therapies. The company’s focus on localized activation of innate immunity positions it to explore a range of hematologic and solid tumor indications, underscoring its ambition to deliver next-generation immunotherapies that offer improved safety and efficacy profiles.AI Generated. May Contain Errors. Read More Bolt Biotherapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks62nd Percentile Overall ScoreBOLT MarketRank™: Bolt Biotherapeutics scored higher than 62% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingHold Consensus RatingBolt Biotherapeutics has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on no strong buy ratings, 2 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialBolt Biotherapeutics has a consensus price target of $41.00, representing about 737.6% upside from its current price of $4.90.Amount of Analyst CoverageBolt Biotherapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Bolt Biotherapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Bolt Biotherapeutics is -0.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Bolt Biotherapeutics is -0.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBolt Biotherapeutics has a P/B Ratio of 0.35. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.40% of the float of Bolt Biotherapeutics has been sold short.Short Interest Ratio / Days to CoverBolt Biotherapeutics has a short interest ratio ("days to cover") of 0.21, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Bolt Biotherapeutics has recently decreased by 69.17%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthWeak Dividend YieldBolt Biotherapeutics does not currently pay a dividend.Dividend GrowthBolt Biotherapeutics does not have a long track record of dividend growth.Read more about Bolt Biotherapeutics' dividend. News and Social Media1.8 / 5News Sentiment-0.06 News SentimentBolt Biotherapeutics has a news sentiment score of -0.06. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Bolt Biotherapeutics this week, compared to 2 articles on an average week.Search Interest3 people have searched for BOLT on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days. Company Ownership1.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Bolt Biotherapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders9.40% of the stock of Bolt Biotherapeutics is held by insiders.Percentage Held by Institutions86.70% of the stock of Bolt Biotherapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Bolt Biotherapeutics' insider trading history. Receive BOLT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bolt Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BOLT Stock News HeadlinesBolt Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Business UpdateMay 12 at 4:05 PM | globenewswire.comBolt Biotherapeutics (NASDAQ:BOLT) Share Price Passes Below Two Hundred Day Moving Average - Should You Sell?May 12 at 3:22 AM | americanbankingnews.comThe cat is out the bagAlmost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered separation packages to 8,500 workers, and Oracle is reportedly eliminating up to 30,000 positions. Goldman Sachs estimates 12,400 Americans are being financially displaced every single day. Analyst Porter Stansberry says the real driver runs deeper than AI - and two Nobel Prize winners have issued the same warning. He calls it the Final Displacement, and he's releasing a full investigation with specific companies to buy and sell before the next wave hits.May 14 at 1:00 AM | Porter & Company (Ad)Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business UpdateMarch 12, 2026 | globenewswire.comBolt Biotherapeutics to Participate in Upcoming March ConferencesFebruary 24, 2026 | globenewswire.comBolt Biotherapeutics Reports Improved Financial PerformanceNovember 13, 2025 | msn.comBolt Biotherapeutics reports Q3 EPS ($3.72), consensus ($5.39)November 12, 2025 | msn.comBolt Biotherapeutics Reports Third Quarter 2025 Financial Results and Provides Business UpdateNovember 12, 2025 | globenewswire.comSee More Headlines BOLT Stock Analysis - Frequently Asked Questions How have BOLT shares performed this year? Bolt Biotherapeutics' stock was trading at $5.47 at the start of the year. Since then, BOLT stock has decreased by 10.5% and is now trading at $4.8950. How were Bolt Biotherapeutics' earnings last quarter? Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) announced its quarterly earnings data on Tuesday, May, 12th. The company reported ($4.31) earnings per share for the quarter, missing the consensus estimate of ($2.85) by $1.46. The company had revenue of $0.03 million for the quarter, compared to analysts' expectations of $1.50 million. Bolt Biotherapeutics had a negative trailing twelve-month return on equity of 91.06% and a negative net margin of 455.15%. When did Bolt Biotherapeutics' stock split? Bolt Biotherapeutics shares reverse split on Monday, June 9th 2025.A 1-20 reverse split was announced. The number of shares owned by shareholders was adjusted after the market closes on Sunday, June 8th 2025. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. When did Bolt Biotherapeutics IPO? Bolt Biotherapeutics (BOLT) raised $213 million in an IPO on Friday, February 5th 2021. The company issued 11,500,000 shares at a price of $18.00-$19.00 per share. Morgan Stanley, SVB Leerink, Stifel and Guggenheim Securities acted as the underwriters for the IPO. How do I buy shares of Bolt Biotherapeutics? Shares of BOLT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Bolt Biotherapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Bolt Biotherapeutics investors own include NIO (NIO), Plug Power (PLUG), Alibaba Group (BABA), Moderna (MRNA), NVIDIA (NVDA) and XPENG (XPEV). Company Calendar Last Earnings5/12/2026Today5/14/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1w+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 For the last 9 days, BOLT's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryBiotechnology Current SymbolNASDAQ:BOLT CIK1641281 Webwww.boltbio.com Phone650-665-9295FaxN/AEmployees90Year Founded2015Price Target and Rating Average Price Target for Bolt Biotherapeutics$41.00 High Price Target$75.00 Low Price Target$7.00 Potential Upside/Downside+720.0%Consensus RatingHold Rating Score (0-4)2.25 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($16.33) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$33.38 million Net Margins-455.15% Pretax Margin-433.74% Return on Equity-91.06% Return on Assets-44.98% Debt Debt-to-Equity Ratio0.76 Current Ratio3.59 Quick Ratio3.59 Sales & Book Value Annual Sales$7.70 million Price / Sales1.25 Cash FlowN/A Price / Cash FlowN/A Book Value$13.81 per share Price / Book0.36Miscellaneous Outstanding Shares1,922,000Free Float1,741,000Market Cap$9.61 million OptionableNot Optionable Beta1.10 Social Links 7 Stocks to Ride The A.I. MegaboomWe are about to experience the greatest A.I. boom in stock market history... Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s. That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom. Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day. And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly... Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy. Get This Free Report This page (NASDAQ:BOLT) was last updated on 5/14/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredPeptide Company Lands Exclusive MMA Wellness PartnershipA publicly traded peptide company just signed an exclusive partnership with a NYSE-listed MMA media platform t...The Tomorrow Investor | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredI’m sounding the alarmMeta is cutting 10% of its workforce. Microsoft offered voluntary retirement to 7% of U.S. employees. Oracle, ...Porter & Company | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredBlackRock, JPMorgan, and Goldman are all stock piling the same asset… are you?BlackRock, JPMorgan, Goldman Sachs, Fidelity, ARK Invest and Andreessen Horowitz are all buying the same asset...Awesomely, LLC | SponsoredDistracted Americans set to miss out on quadrillionsTechnology expert and Washington D.C. insider Jeff Brown - who identified Bitcoin, Tesla, and Nvidia early - s...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bolt Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bolt Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
